Solid Biosciences Inc. (SLDB) NASDAQ
6.58
-0.61(-8.48%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
6.58
-0.61(-8.48%)
Currency In USD
| Previous Close | 7.19 |
| Open | 7.06 |
| Day High | 7.14 |
| Day Low | 6.56 |
| 52-Week High | 8.87 |
| 52-Week Low | 3.34 |
| Volume | 1.58M |
| Average Volume | 1.29M |
| Market Cap | 512.65M |
| PE | -3.43 |
| EPS | -1.92 |
| Moving Average 50 Days | 7.43 |
| Moving Average 200 Days | 6.2 |
| Change | -0.61 |
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
GlobeNewswire Inc.
Mar 11, 2026 5:01 PM GMT
- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in muscle int
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
GlobeNewswire Inc.
Mar 06, 2026 1:31 PM GMT
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securiti
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 06, 2026 1:30 PM GMT
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its next-